Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
4 Companies That Could Upend the Pharma Industry
01:27pm, Wednesday, 29'th Jul 2020
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
12:30pm, Tuesday, 28'th Jul 2020
* Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechno
Allogene Therapeutics (NASDAQ:ALLO) Downgraded by BidaskClub
05:38am, Monday, 27'th Jul 2020
BidaskClub lowered shares of Allogene Therapeutics (NASDAQ:ALLO) from a buy rating to a hold rating in a research note published on Friday, BidAskClub reports. Several other brokerages also recently c
Vident Investment Advisory LLC Cuts Stock Position in Allogene Therapeutics Inc (NASDAQ:ALLO)
06:22am, Wednesday, 22'nd Jul 2020
Vident Investment Advisory LLC decreased its holdings in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) by 33.5% during the second quarter, according to its most recent filing with the Securities a
Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announc
Did Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insiders Buy Up More Shares?
11:55am, Wednesday, 15'th Jul 2020
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
The SAB comprises experts across oncology, immunology, cell therapy, and drug discovery and development. “We are privileged to welcome Drs. Gajewski and Grupp to our Scientific Advisory Board,”
Allogene Therapeutics Inc (NASDAQ:ALLO) Short Interest Update
02:54am, Tuesday, 07'th Jul 2020
Allogene Therapeutics Inc (NASDAQ:ALLO) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 11,490,000 shares, a decline of 13.3% from the
Allogene Therapeutics, Inc. (ALLO): Hedge Funds Sticking Around
07:31pm, Sunday, 05'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Group Holdings (Sbs) Advis Tpg Sells 500 Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) Stock
07:19am, Thursday, 02'nd Jul 2020
Allogene Therapeutics Inc (NASDAQ:ALLO) major shareholder Group Holdings (Sbs) Advis Tpg sold 500 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average
Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer
12:00am, Thursday, 02'nd Jul 2020
Rexgenero, a regenerative medicine company appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer.
Insider Sells Allogene Therapeutics Shares
02:54pm, Wednesday, 01'st Jul 2020
Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) moved lower by 2% from the previous closing price. A Form 4 filing filed with the SEC on Monday, June 29 showed that Tpg Group Holdings Sbs) Advisors,
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
12:30pm, Wednesday, 01'st Jul 2020
Considered one of the highest distinctions in science for researchers working in the Netherlands, a maximum of two Stevin Prizes are awarded by the Dutch Research Council (NWO) each year to a research
Atreca (BCEL) Received its Third Buy in a Row - Markets
10:27am, Wednesday, 01'st Jul 2020
After H.C. Wainwright and Cowen & Co. gave Atreca (NASDAQ: BCEL) a Buy rating last month, the company received another
Insiders Roundup: Salesforce, Mastercard
07:30pm, Friday, 26'th Jun 2020
Largest insider trades of the week Continue reading...
